- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about GHRS
Recent news which mentions GHRS
'Big 5" Psychedelic-Based Biotech Stocks Up 34% YTD
August 19, 2025
From TalkMarkets
From Benzinga
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 20, 2025
From Benzinga
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 03, 2025
From Benzinga
Crude Oil Moves Higher; Owens & Minor Shares Plummet
February 03, 2025
From Benzinga
Dow Falls 150 Points; ISM Manufacturing PMI Rises In January
February 03, 2025
From Benzinga
IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday
February 03, 2025
From Benzinga
Why Is GH Research Stock Trading Higher On Monday?
February 03, 2025
From Benzinga
S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results
February 03, 2025
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 03, 2025
From Benzinga
Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
February 03, 2025
From Benzinga
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 22, 2025
From Benzinga
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
September 05, 2024
From Benzinga
3 Psychedelic Stocks to Ride to the Moon and Beyond
July 06, 2024
From InvestorPlace
From InvestorPlace
From Benzinga
Tickers
GHRS
From InvestorPlace
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
From Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
From Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
From Benzinga
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
From Benzinga
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
February 29, 2024
From Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
From Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
From Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
From Benzinga
From Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.